PepGen Ltd (PEPG)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $410.98M
Last updated: Nov 17, 2026 at 11:05 AM ET
PepGen Ltd (PEPG) Competitors
The companies most similar to PepGen are Prothena Corporation (PRTA), Neurogene (NGNE) and Precision BioSciences (DTIL). By market cap, PepGen ranks 8th of the 13 companies on this page; Geron (GERN) is the largest at $622.98M.
Peer Comparison
PEPG's revenue growth of 0.0% is below the peer median of 0.3%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| PepGen (PEPG) | $410.98M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Prothena Corporation plc (PRTA) | $419.01M | N/A | 7.8x | -45.4% | N/A | -74.3% | 0.00% |
| Neurogene Inc (NGNE) | $495.37M | N/A | N/A | 0.0% | -28.5% | 0.0% | 0.00% |
| Precision BioSciences Inc (DTIL) | $288.76M | N/A | 4.4x | -85.6% | -38.3% | 37272.0% | 0.00% |
| Regenxbio Inc (RGNX) | $505.18M | N/A | 3.1x | -113.9% | N/A | -69.2% | 0.00% |
| Puma Biotechnology Inc (PBYI) | $401.70M | 15.0x | 1.6x | 10.3% | N/A | 1.1% | 0.00% |
| Tevogen Bio Holdings Inc. (TVGN) | $406.59M | N/A | N/A | 0.0% | 2022.8% | 0.0% | 0.00% |
| Rezolute Inc (RZLT) | $353.54M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Gyre Therapeutics Inc. (GYRE) | $471.74M | N/A | 3.8x | -22.7% | N/A | 0.7% | 0.00% |
| Tectonic Therapeutic, Inc. (TECX) | $413.27M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Editas Medicine Inc (EDIT) | $334.92M | N/A | 5.6x | -145.0% | -42.3% | 37.4% | 0.00% |
| Geron Corporation (GERN) | $622.98M | N/A | 2.9x | -22.0% | -7.4% | 27.4% | 0.00% |
| Phathom Pharmaceuticals Inc (PHAT) | $492.63M | N/A | 1.8x | -30.2% | 11.4% | 71.1% | 0.00% |
| Peer median | $416.14M | 15.0x | 3.5x | -22.4% | -18.0% | 0.3% | 0.00% |
Similar Companies
These are the 12 companies most similar to PepGen, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Prothena Corporation plc (PRTA) | Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases... | PRTA competitors |
| Neurogene Inc (NGNE) | Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders... | NGNE competitors |
| Precision BioSciences Inc (DTIL) | Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. | DTIL competitors |
| Regenxbio Inc (RGNX) | REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable... | RGNX competitors |
| Puma Biotechnology Inc (PBYI) | Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States... | PBYI competitors |
| Tevogen Bio Holdings Inc. (TVGN) | Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology... | TVGN competitors |
| Rezolute Inc (RZLT) | Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States. | RZLT competitors |
| Gyre Therapeutics Inc. (GYRE) | Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. | GYRE competitors |
| Tectonic Therapeutic, Inc. (TECX) | Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel... | TECX competitors |
| Editas Medicine Inc (EDIT) | Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. | EDIT competitors |
| Geron Corporation (GERN) | Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic... | GERN competitors |
| Phathom Pharmaceuticals Inc (PHAT) | Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. | PHAT competitors |
Frequently Asked Questions About PEPG
Who are PepGen's main competitors?
The companies most similar to PepGen include Prothena Corporation (PRTA), Neurogene (NGNE), Precision BioSciences (DTIL), Regenxbio (RGNX) and Puma Biotechnology (PBYI), listed from the closest match.
Who is PepGen's biggest competitor?
Geron (GERN) is the largest of the similar companies at $622.98M; Prothena Corporation (PRTA) is the closest match by business profile, size, sector and industry.
How does PEPG stock compare with its competitors?
PEPG's net margin is 0.0% against a peer median of -22.4%.
Which of PepGen's competitors pays a higher dividend?
PepGen pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is PepGen bigger than its competitors?
No. PepGen is 8th by market cap among the 13 companies on this page; the largest is Geron (GERN) at $622.98M.
PEPG pages: Overview, Earnings, Forecast, Financials, Competitors